MacroCure

The company's business model centered on gaining regulatory approval and marketing CureXcell globally. In Israel, CureXcell received marketing authorization as a medical device and was used to treat over 5,000 patients, with reimbursement approval from the Israeli Ministry of Health. To fund its expansion and costly clinical trials in North America and other regions, MacroCure pursued public financing. The company secured multiple rounds of funding from investors including Viola Group, Pontifax, and Docor International Management. This culminated in a significant milestone in July 2014, when MacroCure went public on the Nasdaq stock exchange under the ticker "MCUR," raising $54 million.

Despite its early success in Israel, MacroCure's trajectory shifted following a critical setback. In October 2015, the company announced that its pivotal Phase III clinical trial for CureXcell in treating DFUs did not meet its primary endpoint, failing to show a statistically significant rate of complete wound closure. This event was a major blow to the company's prospects. Following the trial failure, MacroCure's board and management explored strategic alternatives, leading to a definitive merger agreement with Leap Therapeutics, Inc. in August 2016. The reverse merger was completed in January 2017, with MacroCure becoming a wholly-owned subsidiary of Leap Therapeutics. Subsequently, MacroCure's stock ceased trading on Nasdaq, and the combined entity continued under the Leap Therapeutics name (LPTX), focusing on immuno-oncology.